FrostPharma is proud and pleased to announce that the company has been successful in the tender bidding process in Norway. The company has been notified of winning two national tender contracts in two different therapeutic areas, starting Feb 1, 2022 and running for two years with option to prolong another two years. This means that the health care providers and patients eligible for these specific treatments will have access to our value-added products throughout the tender contract period in Norway. The therapeutic areas in scope for these two treatments are sedation and anti-thrombotic treatment.
top of page
För Nyheter och Media
Senaste inläggVisa alla
FROSTPHARMA ENTERS AGREEMENT WITH ADVICENNE FOR MARKETING AND DISTRIBUTION OF SIBNYAL® IN THE NORDIC
FrostPharma AB announces signature of an exclusive Distribution Agreement with Advicenne for marketing and distribution of Sibnayal® in Denmark, Finland, Norway, Iceland and Sweden. Under the terms of
During her tenure as CEO for FrostPharma AB, Cecilia Bröms-Thell has invested and prepared the FrostPharma business for accelerated growth while securing solid performance of the in-line portfolio. Th
bottom of page